Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEVRAD: Pembrolizumab + Enfortumab vedotin with bladder-preserving radiotherapy in muscle-invasive bladder cancer
jRCT2051230071Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and enfortumab vedotin in muscle-invasive urothelial bladder carcinoma (MIBC), sponsored by Merck & Co. Primary endpoint: Bladder intact event-free survival (BI-EFS) rate. Started Oct 2023; status: active, not recruiting.
02
Drugs
pembrolizumabenfortumab vedotin
03
Conditions
muscle-invasive urothelial bladder carcinoma (MIBC)
Beyond the preview
Go deeper on jRCT2051230071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230071.